SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

I

Check this box if no longer subject to Section 16. Form 4 or Form 5 biligations may continue. <i>See</i>	STATEMENT OF CHANGES IN
obligations may continue. See Instruction 1(b).	Filed pursuant to Section 16(a) of the

I BENEFICIAL OWNERSHIP

Securities Exchange Act of 1934 nent Company Act of 1940 or Section 30(h) of the Invest

1	0									
	OMB Number:	3235-0287								
	Estimated average burden									
	hours per response:	0.5								

	of Section So(n) of the investment company Act of 1340									
1. Name and Address of Reporting Person [*] Shealy Ben	2. Issuer Name and Ticker or Trading Symbol <u>Diffusion Pharmaceuticals Inc.</u> [DFFN]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify								
(Last) (First) (Middle) 1317 CARLTON AVENUE, SUITE 400	3. Date of Earliest Transaction (Month/Day/Year) 01/02/2018	Sr VP Finance & Treasurer								
(Street) CHARLOTTESVILLE VA 22902 (City) (State) (Zip)	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person								
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned										

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	if any	Transaction Code (Instr.		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership
			Code	v	Amount	(A) or (D)	Price	Reported Transaction(s) (Instr. 3 and 4)		(Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transa Code (8)		of		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Stock Option (Right to Buy)	\$1.18	01/02/2018		A		25,000		(1)	01/02/2028	Common Stock	25,000	\$0	25,000	D	

Explanation of Responses:

1. The shares underlying the options vest in 36 equal (or as nearly equal as possible) monthly installments on the last calendar day of each month over a three-year period beginning on January 31, 2018.

/s/ Ben Shealy

** Signature of Reporting Person

01/04/2018

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.